Trial results for a Phase II study (NCT02873962) investigating Nivolumab in combination with Bevacizumab and Rucaparib for relapsed ovarian, fallopian tube, or peritoneal cancer were posted on ClinicalTrials.gov on 2026-04-01. The study included cohorts evaluating objective response rate, with 11 participants showing objective response in the Nivolumab and Bevacizumab cohort.
Background
This Phase II study evaluated Nivolumab, Bevacizumab, and Rucaparib as a possible treatment for relapsed ovarian, fallopian tube, or peritoneal cancer. These cancers are often challenging to treat, especially in the relapsed setting.
Trial design
The study (NCT02873962) was a Phase II trial that enrolled 72 participants. It investigated Nivolumab, Bevacizumab, and Rucaparib as a potential treatment for relapsed ovarian, fallopian tube, or peritoneal cancer. The trial was structured with different cohorts to assess the combinations of these interventions.
Key results
The trial results reported key measurements for objective response rate and tolerability across different cohorts:
- For the outcome "Objective Response Rate" in Cohort 1: Nivolumab and Bevacizumab, 11 participants showed an objective response.
- For the outcome "Objective Response Rate" in Cohort 2: Nivolumab With Bevacizumab and Rucaparib, 3 participants showed an objective response.
- For the outcome "Tolerability" in Cohort 3: Nivolumab With Bevacizumab and Rucaparib, 1 participant was reported.
What this means
The posted trial results provide initial data on objective response rates and tolerability for different combinations of Nivolumab, Bevacizumab, and Rucaparib in patients with relapsed ovarian, fallopian tube, or peritoneal cancer. These early-phase findings contribute to the understanding of these drug combinations in this challenging patient population. Further detailed analysis and subsequent studies would be necessary to fully assess the clinical utility and efficacy of these regimens.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT02873962, titled "A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib," were posted on 2026-04-01 on clinicaltrials.gov.